Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress Agrees To Keep FDA, Other Agencies Running At Current Funding Level Through Mid-December

Executive Summary

The US Congress this week agreed to keep the FDA and other government agencies funded at fiscal-year 2019 levels, extending the continuing resolution another four weeks until 20 December.

You may also be interested in...



US Senate Recommends Funding For FDA Device Shop In 2020 To Support Cybersecurity, Virtual Trials

The US Senate Appropriations Committee passed FDA funding levels for 2020 on 19 September that would support medical device cybersecurity and medtech manufacturing, but a continuing resolution measure is waiting in the wings to provide the full Senate more time to consider the measure before the new fiscal year starts on 1 October.

Bumps In The Road As US FDA Tries To Catch Up From Shutdown

The recently ended record-setting US government shutdown is not anticipated to have a long-term impact on US FDA device review times. But agency reviewers will face more 510(k) review deadline pressures than usual and may have limited availability for pre-submission meetings in the short term, one expert suggests.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel